Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Breast Neoplasms 5Small Cell Lung Carcinoma 3Thoracic Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Neoplasms 2Lung Diseases 2Carcinoma, Large Cell 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Retinoblastoma 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Non-small Cell Lung Cancer Metastatic 1Non-Small Cell Lung Cancer Metastatic 1Neoplasms, Second Primary 1Neoplasms by Site 1Nasopharyngeal Neoplasms 1NSCLC 1Medulloblastoma 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Bronchogenic 1Carcinoma 1Cancer Therapy-related Cardiovascular Toxicity 1Bronchial Neoplasms 1Adenocarcinoma of Lung 1

Interventions

sacubitril and valsartan sodium hydrate drug combination 1icotinib 1Thalidomide 1Megestrol Acetate 1Isotretinoin 1Drug Therapy 1Doxycycline 1Docetaxel 1Carboplatin 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms, Second Primary × Carboplatin × Clear all
NCT02283424 2014-11-05

Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation

Chinese PLA General Hospital

Phase 4 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡